Back
Past, present and future of gene expression-tailored therapy for lung cancer.
Journal article

Past, present and future of gene expression-tailored therapy for lung cancer.

  • Marrer E Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/salahdine.chibout@novartis.com.
  • Baty F University Hospital Basel, Pulmonary Gene Research, Basel, Switzerland. batyf/mbrutsche@uhbs.ch.
  • Kehren J Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/salahdine.chibout@novartis.com.
  • Chibout SD Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/salahdine.chibout@novartis.com.
  • Brutsche M University Hospital Basel, Pulmonary Gene Research, Basel, Switzerland. batyf/mbrutsche@uhbs.ch.
  • 2018-05-26
Published in:
  • Personalized medicine. - 2006
biomarkers
classification
diagnosis
genomics
lung cancer
personalized medicine
prognosis
English "Variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions which we know as disease." Sir William Osler (1849-1919). All human beings are different and some of these differences are the variations in response to xenobiotics. Personalized medicine means: the right patient population, the right drug, the right dose, the right indication, and administration at the right time. This review provides an update on concepts of personalized therapy for lung cancer.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/160128
Statistics
Document views: 18 File downloads: